Cobra Biologics, QuiaPEG Pharmaceuticals Partner in PEGlyation

By Supplier News - DCAT Publisher

June 24, 2014

Cobra Biologics, a contract manufacturer of biologics and related service, and QuiaPEG Pharmaceuticals AB, an  biotechnology company, have announced a strategic alliance focused on the processing of biological drugs to increase half-life and reduce production costs by using a new PEGylation technology platform. 

PEGylation is the modification of a protein, peptide or non-peptide molecule by linking polyethylene glycol (PEG) chains to extend a drugs effect by reducing degradation, and reducing the rate of excretion by the kidneys and the formation of antibodies against the protein. PEGylation plays a key role in modern drug delivery.

Source: Cobra Biologics